Related Experiment Video
Updated: Jan 30, 2026

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
Published on: October 1, 2015
[4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)]
Dietrich Hüppe1, Yvonne Serfert2, Peter Buggisch3
1Gastroenterologische Gemeinschaftspraxis Herne, Herne.
Background:
More than 250 000 patients suffer from chronic hepatitis C in Germany. Several potent, direct-acting antiviral drugs have been approved since 2014. The aim of the German Hepatitis C-Registry (DHC-R) is to describe the epidemiology and patient care of hepatitis C and to investigate the efficacy and safety of new treatment options in real-world settings.
Methods:
The DHC-R is a prospective multicenter non-interventional registry study that includes 327 centers throughout Germany. All approved treatment options have been documented. The current analysis differentiated 4 phases: 2/2014 - 12/2014, 1/2015 - 12/2015, 1/2016 - 7/2017 and 8/2017 - 7/2018.
Findings:
Between February 2014 and July 2018, 12 170 patients were included in the registry (61.3 % male), and antiviral treatment was initiated in 11 268. The mean age declined from 52.3 years (phase 1) to 49.3 years (phase 4), while the proportion of patients with previous or ongoing drug abuse increased (26.3 % to 43.1 %). In 2014, 35.1 % of treated patients had liver cirrhosis, which declined to 16.5 % in phase 4. The HCV genotype distribution showed marked fluctuations, with most recent increases in HCV genotype 3 (30 % in phase 4). Per-protocol sustained virological response rates increased from 92.8 % in 2014 to 94.4 % in 2017/18 with excellent tolerability.
Summary:
The DHC-R mirrors patient care of chronic hepatitis in the real-world setting in Germany and provides insights into epidemiology developments. It also confirms the high efficacy and safety of novel treatment options.
Insights
The German Hepatitis C Registry (DHC-R) shows new antiviral treatments for chronic hepatitis C are highly effective and safe in real-world German patient care. Registry data confirms excellent tolerability and sustained virological response rates.
Area of Science:
- Hepatology
- Virology
- Public Health
Background:
- Chronic hepatitis C affects over 250,000 individuals in Germany.
- Recent approval of potent direct-acting antiviral drugs has transformed treatment landscapes.
- The German Hepatitis C-Registry (DHC-R) was established to monitor patient care and treatment outcomes.
Purpose of the Study:
- To describe the epidemiology of hepatitis C in Germany.
- To evaluate patient care patterns for chronic hepatitis C.
- To assess the real-world efficacy and safety of newly approved antiviral therapies.
Main Methods:
- Prospective, multicenter, non-interventional registry study across 327 German centers.
- Documentation of all approved hepatitis C treatment options.
- Analysis divided into four distinct time phases from February 2014 to July 2018.
Main Results:
- Over 11,000 patients initiated antiviral treatment between 2014 and 2018.
- Mean patient age decreased, while the proportion with a history of drug abuse increased.
- Significant reduction in liver cirrhosis prevalence among treated patients.
- Sustained virological response rates exceeded 94% with excellent tolerability.
Conclusions:
- The DHC-R effectively reflects real-world hepatitis C patient management in Germany.
- The registry provides valuable insights into evolving hepatitis C epidemiology.
- Novel antiviral treatments demonstrate high efficacy and safety in clinical practice.
Related Concept Videos
Direct-Acting Cholinergic Agonists: Pharmacokinetics
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Forces Acting on Chromosomes
Microtubules and motor proteins exert two types of forces on...

